Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Corcoran on Future of Liquid Biopsies in GI Cancers

December 27th 2018

Ryan B. Corcoran, MD, PhD, clinical researcher, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the future role of liquid biopsies in gastrointestinal cancers.

UVA Screening Program Seeks to Get Ahead of Colorectal Cancer

December 26th 2018

Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.

Dr. Strickler on Applications for Liquid Biopsies in GI Cancer

December 21st 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses applications for liquid biopsies in gastrointestinal cancer.

Augmenting T-Cell Immunity in Pancreatic Cancer

December 21st 2018

Stephanie K. Dougan, PhD, assistant professor, Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways of augmenting T-cell immunity in pancreatic cancer.

Dr. Overman on Next Steps With Immunotherapy in mCRC

December 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Dr. Lenz on Potential for Immunotherapy in mCRC

December 20th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.

Dr. Sugarbaker on Perioperative Chemotherapy in Gastrointestinal Cancer

December 20th 2018

Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at MedStar Washington Hospital Center, discusses the use of perioperative chemotherapy in the treatment of patients with gastrointestinal (GI) cancer.

Dr. Corcoran on Benefits/Limitations of Liquid Biopsies in GI Cancer

December 19th 2018

Ryan B. Corcoran, MD, PhD, clinical researcher, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the benefits and limitations of liquid biopsies in gastrointestinal cancer.

Dr. Bekaii-Saab on Challenges With Precision Medicine in CRC

December 19th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the challenges of bringing a precision medicine approach into the clinic in colorectal cancer.

Eryaspase May Provide Second-Line Option in Pancreatic Cancer

December 18th 2018

Pascal Hammel, MD, PhD, discusses the potential for eryaspase, and the future direction of the pancreatic cancer landscape.

DKK3 Gene Linked to Pancreatic Adenocarcinoma Proliferation

December 12th 2018

An investigational antibody directed against Dickkopf-3 may be the key in suppressing tumor growth and extending survival in patients with pancreatic adenocarcinoma.

Dr. Benson on Considerations for Advanced CRC Treatment

December 12th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the factors to consider when approaching treatment for a patient with advanced colorectal cancer.

Dr. Greten Discusses the Impact of the Gut Microbiome on Liver Tumors

December 12th 2018

Tim F. Greten, MD, senior investigator, Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, discusses the impact of the gut microbiome on liver tumors.

Expert Highlights TAS-102 Potential in Gastric/GEJ Cancer

December 11th 2018

Although gastric and gastroesophageal junction cancers are heterogeneous diseases with a number of FDA-approved regimens, TAS-102 may have a place in the management of previously treated patients, according to Hendrik-Tobias Arkenau, MD, PhD.

Experts Highlight Developments in Lung, GI Cancers

December 11th 2018

Recent data have moved the needle across the board in oncology, specifically with lung cancer and gastrointestinal cancers, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes.

Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer

December 6th 2018

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer.

Dr. Strickler on the Importance of Molecular Markers in mCRC

December 6th 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses improvements in the treatment of metastatic colorectal cancer.

GI Cancer Treatment Continues to Evolve, But Unmet Needs Remain

December 1st 2018

Cathy Eng, MD, shares her insight on the current paradigm of gastrointestinal cancers, specifically colorectal cancer and hepatocellular carcinoma.

Luminary Awards in GI Cancers Honor Distinguished Leaders

November 30th 2018

Five leaders in the fight against gastrointestinal cancers from academia, the community, and clinic were honored at the 2018 Luminary Awards.

Dr. O'Connor Discusses Regorafenib Dosing in mCRC

November 30th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.